^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor) +
    AB-329 (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer

    Published date:
    01/09/2023
    Excerpt:
    This was a multicenter, open-label Phase 1 study of DS-1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR-mutant NSCLC...25% of patients had stable disease (n = 5) and 70% (n = 14) experienced disease progression as the best overall response. The disease control rate was 25% (95% CI: 8.7–49.1).
    DOI:
    https://doi.org/10.1002/cam4.5508
    Trial ID:
    NCT03599518